First Tracks Biotherapeutics TRAX
NASDAQ TRAX
$46.56 -0.54 (-1.15%)
At close: Nov 16, 2026 · 4:00 PM EST

First Tracks Biotherapeutics (TRAX) Total Non-Current Liabilities (2026)

Updated

First Tracks Biotherapeutics' Total Non-Current Liabilities came in at $14.26 million for Q1 2026.

Analysis

First Tracks Biotherapeutics (TRAX) Total Non-Current Liabilities (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn 60.81 Bn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn 102.65 Bn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn 117.60 Bn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 79.95 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn -36.84 Bn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn 76.12 Bn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn 36.05 Bn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn 96.04 Bn
10 First Tracks Biotherapeutics 1.66 Bn 740.14 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 14.26 Mn
API Access

First Tracks Biotherapeutics Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=TRAX&period=max&api_key=YOUR_API_KEY